Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006)

Original article by: JR Daw, B Mintzes, MR Law, GE Hanley, SG Morgan

Reference: Clinical Therapeutics Jan 2012;34(1):239-249.e2

Source: Clinical Therapeutics

Keywords: Benzodiazepines; Canada; Drug Utilisation; Drugs-Prescribed; Preconception Period; Pregnancy;

Date published: 26/01/2012 17:04

Summary
by: Pharm-line

Background: Owing to the paucity of evidence available on the risks and benefits of drug use in pregnancy, the use of prescription medicines is a concern for both pregnant women and their health care providers.

Objective: The aim of this study was to measure the frequency, timing, and type of medicines used before, during and after pregnancy in a Canadian population.

Methods: This retrospective cohort analysis used population-based health care data from all pregnancies ending in live births in hospitals in British Columbia, Canada, from Apr 2001 to Jun 2006 (n = 163,082).  Data from hospital records were linked to those in outpatient prescription-drug claims.  Data from prescriptions filled from 6 months before pregnancy to 6 months postpartum were analysed.  Drugs were classified by therapeutic category and US Food and Drug Administration (FDA) pregnancy risk categories.

Results: Prescriptions were filled in 63.5% of pregnancies.  Evidence on safety is limited for many of the medicines most frequently filled in pregnancy, including codeine, salbutamol and betamethasone.  At least 1 prescription for a category D or X medicine was filled in 7.8% of pregnancies (5.5% category D; 2.5% category X).  The most frequently filled prescriptions for category D drugs were benzodiazepines and antidepressants.  The most frequently filled prescriptions for category X drugs were oral contraceptives and ovulation stimulants filled in the first trimester.

Conclusions: The majority of pregnant women in British Columbia filled at least 1 prescription, and about 1 in 13 filled a prescription for a drug categorised as D or X by the FDA.  The prevalence of maternal prescription drug use emphasises the need for postmarketing evaluation of the risk-benefit profiles of pharmaceuticals in pregnancy.  Future research on prenatal drug use based on administrative databases should examine maternal treatment adherence and the determinants of maternal drug use, considering maternal health status, sociodemographics and the characteristics and providers of prenatal care.

About this library entry

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.